Using a multidisciplinary case-based approach, this activity discusses recent studies important for the management of gynecologic cancer. The activity includes a gynecologic pathologist for review and discussion of the significance of recent additions to gynecologic pathology reports that are becoming more common, including the four molecular groups and extent of lymphovascular invasion (LVI) for endometrial cancer, HPV status for vulvar cancer, and PD-L1 expression for cervical cancer. The endometrial case discussion highlights the updates in FIGO staging with the inclusion of molecular status and LVI, emerging data suggesting molecular status should influence treatment approach for endometrial cancers and role of immunotherapy for advanced stage disease. The vulvar and cervical cancer case discussions highlight how to use pathologic features, such as HPV status and PD-L1 expression to help guide treatment approach. Additionally, how to interpret recently reported contrasting data, in particular for immunotherapy and neoadjuvant chemotherapy, for locally advanced cervical cancer are reviewed to help optimize patient selection for these new treatment approaches for definitive management.